Skip to Content

Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial CTSUBREC40603-M


Randomized Phase II 2 X 2 Factorial Trial Of The Addition Of Carboplatin +/- Bevacizumab To Neoadjuvant Weekly Paclitaxel Followed By Dose-Dense AC In Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer

Principal Investigator(s)

John Murray


  • Protocol No. CTSUBREC40603-M
  • Open Date: 12/07/2010
  • Staging: Phase II
  • Age Group: Adults
  • Scope: National
  • Objective:
  • Disease Sites: Breast
  • Therapies: Chemotherapy - cytotoxic
  • Drugs: None Specified
  • Participating Institutions: Baptist Hospital; Meharry Medical College
  • Secondary Protocol No: Not Specified


None Provided.


Not provided. Please call for more information.